来源:[1] Syndax Pharmaceuticals:Revumenib PDUFA 审查 mNPM1 AML 并迈向 MSS CRC (https://seekingalpha.com/article/4821782-synd ...)[2] Syndax 公布 2025 年第二季度财务业绩并提供业务更新 (https://vertexaisearch.cloud.google.com/groun ...)[3] Stifel 恢复对 Syndax Pharmaceuticals 股票的覆盖,评级为买入 - Investing.com (https://vertexaisearch.cloud.google.com/groun ...)